High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$25.3M
$25,328,349
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Davidson Michael H.
• CEO
Discretionary SellΔOwn -71.8%
2026-03-02
$14,753,258MEGA
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
Discretionary SellΔOwn -71.8%
|
2026-03-02 | $14,753,258MEGA | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Davidson Michael H.
• CEO
10b5-1 Sell
2026-02-26
$6,179,974Whalex2
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-26 | $6,179,974Whalex2 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Davidson Michael H.
• CEO
10b5-1 Sell
2026-02-25
$2,056,174Largex3
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-25 | $2,056,174Largex3 | S | Form 4 |
|
NAMS
S
NewAmsterdam Pharma Co N.V.
Davidson Michael H.
• CEO
10b5-1 Sell
2026-02-24
$2,338,943Largex2
|
||||||
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
10b5-1 Sell
|
2026-02-24 | $2,338,943Largex2 | S | Form 4 |
| NAMS |
NewAmsterdam Pharma Co N.V.
|
CEO
Sell to Cover
|
2026-01-07 | $0 | S | Form 4 |